IP Library › Granted Patent US 11,116,838
Granted Patent B2
US 11,116,838 · App. 15/546,740 · Granted Sep 14, 2021

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Inventors: David Weiner (Merion, PA); Karuppiah Muthumani (Cherry Hill, NJ); Niranjan Sardesai (Blue Bell, PA)
Assignees: The Trustees of the University of Pennsylvania; INOVIO PHARMACEUTICALS, INC.
A61K39/395A61K39/0011A61K39/001153A61K39/001156A61K39/001157A61K39/001186A61K39/001188A61K39/001189A61K39/12A61K39/39558C07K16/2803C07K16/2818C07K16/2827A61K2039/505A61K2039/53A61K2039/545A61K2039/585C07K2317/76C12N2710/20034Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,116,838
App. No.
15/546,740
Granted
Sep 14, 2021
Kind
B2
Abstract

Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.

Claims (5)

1. A composition for generating hTERT-specific CD3+CD8+ T cells displaying double release of the cytokines IFNγ and TNFα in a subject in need thereof, comprising:

a) a monoclonal TIM-3 antibody or a monoclonal LAG-3 antibody, and

b) a nucleic acid molecule comprising a nucleotide sequence encoding a synthetic hTERT antigen.

2. The composition of claim 1 wherein the synthetic antigen is an isolated DNA that encodes for the antigen.

3. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

Continuity (2)
Provisional Application 62109580 · Jan 29, 2015
Related Publication 20180015161A1 · Jan 18, 2018